Sign up to save your podcasts
Or
Share Healthcare: How Much Do Share Prices Matter In Big-Cap Biotech?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Healthcare: How Much Do Share Prices Matter In Big-Cap Biotech?
We compare Biogen's and Celgene's current valuations and consider what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
View all episodes
By The Motley FoolWe compare Biogen's and Celgene's current valuations and consider what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.